EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor
cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach
cancer) or non-small cell lung cancer. EF5 may be effective in measuring oxygen in tumor
tissue. Photosensitizing drugs such as motexafin lutetium are absorbed by tumor cells and,
when exposed to light, become active and kill the tumor cells. Knowing the level of oxygen in
tumor tissue and the level of motexafin lutetium absorbed by tumors and normal tissue may
help predict the effectiveness of anticancer therapy